Gain Client Recognition Again! Medicilon won the 2023 SicaGene "Best Partner Award"

Recently, Shanghai Medicilon Inc. (Medicilon) won the "Best Partner Award" from SicaGene.  The strong support provided in collaboration projects has been recognized by client again.

Medicilon and SicaGene: Go Deep Alone, Go Far Together

The collaboration stems from a shared vision in the field of nucleic acid drugs.  Antisense oligonucleotide drugs can break through the "undruggable targets" limitations of traditional small molecule drugs, but they also have extremely high technical barriers and development difficulties.  As one of the first China innovative pharmaceutical companies to enter the ASO field, SicaGene has independently developed and constructed core technology platforms such as  SicaScreen^TM、SicaChemistry^TM、SicaDelivery^TM , focusing on drug development in the fields of cardiovascular disease, viruses, and ophthalmology.  SicaGene has also achieved efficient development of ASO drugs with high activity, low dosage, long administration cycle, good clinical tolerance and controllable cost.

It is also Medicilon's vision to improve the druggability and R&D efficiency of nucleic acid drugs and help nucleic acid drugs benefit the world.  To this end, Medicilon relies on the Nucleic Acid Drug R&D Service Platform to empower SicaGene's ASO drug research and development, and the trust and support from SicaGene also encourage Medicilon to continue to innovate and improve.  Through close collaboration between the two parties, the collaboration has achieved positive progress and phased results.

Nucleic Acid Drug R&D Service Platform provides one-stop support for R&D

Medicilon's Nucleic Acid Drug R&D Service Platform is an integrated and comprehensive platform that integrates drug discovery, production and preclinical research.  Based on a rigorous scientific attitude, an open technology platform and advanced instruments and equipment, Medicilon can provide nucleic acid drug discovery, screening and preclinical research services to pharmaceutical companies and scientific research institutions.

Medicilon will continue to target cutting-edge tracks such as nucleic acid, cell and gene therapy, PROTAC, and ADC, strengthen technological innovation, and gather superior resources to provide clients with a one-stop biopharmaceutical preclinical R&D service platform and to empower global partners to accelerate pharmaceutical innovation.